Like its predecessor, “Wicked: For Good” more than doubles the runtime of Act II of the Broadway musical that inspired it. But unlike the first “Wicked” film, the sequel makes big additions to the ...

Netflix’s The Hunting Wives is a salacious and sultry murder mystery — but how does the TV adaptation compare to the original book? “There are a lot of similarities to the book, and then not,” Lowes ...

In a recent social media post, Peter Ray, senior director of medicinal chemistry at Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX), drew attention to a new article in WIRED from Veronique Greenwood ...

– Company Eligible to Receive Up to $25 Million, Including an Upfront Equity Payment of $7.5 Million – – Extends Rallybio Cash Runway to Mid-2027 – The REV102 program originated from a joint venture ...

While dementia and Alzheimer’s disease are terms that are often used interchangeably, they don’t mean the same thing. Understanding the difference isn’t just helpful for clarity, it’s essential for ...

Boltz-2 is the first biomolecular co-folding model to combine structure and binding affinity prediction, approaching the accuracy of physics-based free energy perturbation (FEP) calculations but at ...

SPOILER ALERT: This post contains spoilers for both seasons of The Last Of Us. HBO‘s television adaptation of the Sony Playstation game The Last Of Us took several departures from its source material ...

If you thought movies based on books that change things made people upset, wait until you see what happens when a beloved animated movie gets the live-action adaptation treatment. Older movies can ...

Recursion Pharmaceuticals' stock has plummeted 57% since February, with significant failures in its lead drug REC-994 and other clinical candidates, raising concerns about its AI-driven drug discovery ...

Shares of Recursion Pharmaceuticals (NASDAQ: RXRX) fell this week. The stock lost 24% as of market close on Friday. The move comes as the S&P 500 and Nasdaq Composite both slipped slightly. Recursion ...

Evidently in the mood for some spring cleaning, Salt Lake City’s Recursion is clearing out a chunk of its pipeline as it narrows its focus on R&D in oncology and rare diseases. The move comes roughly ...